Dallas, TX -- (SBWIRE) -- 05/14/2014 -- The report titled "Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)" provides an in-depth analysis of global rheumatoid arthritis market with special focus on biologics drugs. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2013-18). Further, key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report.
Johnson & Johnson
Roche Holdings AG
Purchase a copy of this report @ http://www.marketreportsonline.com/contacts/purchase.php?name=295942.
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that principally attacks synovial joints. It is one of the most common autoimmune diseases affecting people of all ages and races. RA affects the lining of joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. It also leads to stiffness, and redness in the joints. The main factor causing rheumatoid arthritis remains unknown. However, according to studies around the world some of the genetic and environmental factors are found to be more probable causers.
Treatment of Rheumatoid Arthritis involves frequent drugs administration as RA is a progressive and incurable disease. Drugs used for treatment of RA are classified as first line agents- consisting of non steroidal anti-inflammatory drugs (NSAIDs) and steroids such as glucocorticoids and second line agents- consisting of disease modifying anti-rheumatic drugs such as chloroquine, gold salts, penicillamine, cyclosporine, and several biological agents like TNF-? and interleukin-1 inhibitors.
Complete report available @ http://www.marketreportsonline.com/295942.html.
Global rheumatoid arthritis market is driven by increase in incidences of RA patients, global ageing population and increasing healthcare expenditure by government of various nations. Factors which are affecting pharmaceutical companies are pricing pressure, patent expiries of RA drugs, high costs of treatments involved and escalating R&D costs. The market is characterized by use of auto-injectors by patients for RA treatment, increase in RA cases in women and FDA approvals for RA drugs.
Major points from Table of Contents (http://www.marketreportsonline.com/295942-toc.html) are listed below:
List of Figures
Figure 1: Normal and Arthritis Joints
Figure 2: Clinical Evolution of Rheumatoid Arthritis Treatment
Figure 3: Rheumatoid Arthritis Drugs Treatment Classification
Figure 4: Global Rheumatoid Arthritis Market Size, 2010-12 (US$ Billions)
Figure 5: Global Rheumatoid Arthritis Market Size Forecast, 2013E-18E (US$ Billions)
Figure 6: Global Rheumatoid Arthritis Biologics Drug Market Size, 2010-12E (US$ Billions)
Figure 7: Global Rheumatoid Arthritis Biologics Drug Market Size Forecast, 2013E-18E (US$ Billions)
Figure 8: Global Rheumatoid Arthritis Biologics Drug Market Share by Types (2013E)
Figure 9: Global Rheumatoid Arthritis Biologics Drug Market Share Forecast (2016E)
Figure 10: Global TNF-? target Rheumatoid Arthritis Antibody Treatment Market Size, 2010-12E
Figure 11: Global TNF-? target Rheumatoid Arthritis Antibody Treatment Market Size Forecast, 2013E-18E
Figure 12: Global TNF-? target Rheumatoid Arthritis Antibody Treatment Market Size by Drug, 2010-12E (US$ Billions)
Figure 13: Global TNF-? target Rheumatoid Arthritis Antibody Treatment Market Size by Drug, 2010-12E (US$ Billions)
Figure 14: Global TNF-? target Rheumatoid Arthritis Antibody Treatment Market Share by Drugs (2012E)
Figure 15: Global TNF-? target Rheumatoid Arthritis Antibody Treatment Market Share by Drugs Forecast (2018E)
Explore more reports on Pharmaceuticals Market @ http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.
Contact firstname.lastname@example.org for further information/ details.